Inpharma Weekly

, Volume 1649, Issue 1, pp 22–22 | Cite as

UCB receives not-approvable letter from US FDA for lacosamide.

Media release
  • 4 Downloads

Keywords

Marketing Neuropathic Pain Medium Release Lacosamide Marketing Approval 

Copyright information

© Adis International Ltd 2008

Personalised recommendations